Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of extending the bonus payments that GPs have received for administering the covid-19 vaccine to care home patients to the vaccination of other difficult to reach groups.
Answered by Nadhim Zahawi
We have made no such assessment.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will implement financial rewards for (a) GPs, (b) vaccination centres and (c) other local health professionals for each vaccine administered that goes above the average number of vaccines administered.
Answered by Nadhim Zahawi
We have no plans to do so.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will issue guidance to hospital trusts on vaccinating vulnerable inpatients against covid-19 on admission rather than discharge.
Answered by Nadhim Zahawi
There are no current plans to issue guidance to hospital trusts on vaccinating vulnerable inpatients against COVID-19 on admission rather than discharge.
Timing of vaccinations for vulnerable inpatients, if they have not already been vaccinated as one of the priority cohorts, would be a decision for clinicians responsible for their care taking into account their risk of contracting COVID-19 relative to the potential impact of the vaccine on their treatment.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to publish percentage rates of covid-19 vaccination for the (a) first and (b) second dose, by priority group, at Clinical Commissioning Group level.
Answered by Nadhim Zahawi
NHS England is continually reviewing the data and information it publishes about COVID-19 and the related vaccine. The level of data published about the vaccination programme has increased since the original dataset was first published.
Further information on vaccination levels across the country is available at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/
The latest data on first and second dose vaccinations is available at the following link:
https://coronavirus.data.gov.uk/details/vaccinations
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking as a result of new customs arrangements to ensure that (a) the sight-preserving eye drops atropine and (b) other medicines sourced inside the EU are able to reach patients and clinical trial participants in the UK.
Answered by Jo Churchill
Our priority is to ensure that patients continue to have access to the medicines and clinical trial supplies they need, including eye medicines such as atropine. We continue to work closely with the pharmaceutical industry, sponsors of clinical trials, the National Health Service, and others in the supply chain to deliver the shared goal of continuity of safe patient care under all circumstances.
The Department wrote to all suppliers of medicines and medical products, including sponsors of clinical trials, coming to the United Kingdom from or via the European Union on 17 November 2020. The letter sets out how we are continuing to work with suppliers and sponsors to deliver our multi-layered approach to mitigate any potential disruption to supply of medicines into the UK, including supplies for clinical trials, now that the UK has left the EU Single Market and Customs Union.
The letter is available at the following link: